Docoh
Loading...

BHC Bausch Health Companies

Filed: 21 Jun 21, 7:00am

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

June 19, 2021

Date of report (Date of earliest event reported)

 

 

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia, Canada 001-14956 98-0448205
(State or other jurisdiction
of incorporation)
 (Commission
file number)
 (IRS Employer
Identification No.)

 

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8
(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Shares, No Par Value BHC New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 21, 2021, Bausch Health Companies Inc. (the “Company”) announced that D. Robert Hale resigned from his role as an independent director of the Company’s Board of Directors (the “Board”), effective as of June 19, 2021. Mr. Hale’s decision to resign from the Board was not due to any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.

A copy of the press release, dated June 21, 2021, announcing the resignation of Mr. Hale, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

  

Description

99.1  Press Release announcing the resignation of D. Robert Hale, dated June 21, 2021

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 21, 2021

 

 

 BAUSCH HEALTH COMPANIES INC.
By: 

/s/ Christina M. Ackermann

 

 Christina M. Ackermann

 

 Executive Vice President, General Counsel, Head of Commercial Operations